ACIU AC Immune SA

11.19
-0.51  -4%
Previous Close 11.7
Open 11.68
Price To Book 3.9
Market Cap 753788501
Shares 67,362,690
Volume 120,458
Short Ratio
Av. Daily Volume 118,693

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 3 trial initiation announced February 28, 2017. Noted July 16, 2018 that trial is fully recruited. Data due 2021.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 commencement of dosing announced November 2, 2017.
RO7105705
Alzheimer’s disease
Phase 1/2 interim data due late-2018.
ACI-24 (anti-Abeta vaccine)
Alzheimer's disease-like characteristics in individuals with Down syndrome
Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
Crenezumab - CREAD 1
Alzheimer’s disease
Phase 2 trial initiation announced August 20, 2018.
ACI-24
Alzheimer’s disease
Phase 2 trial planned.
ACI-35
Alzheimer’s disease

Latest News

  1. Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug
  2. Lilly partners with AC Immune for Alzheimer's treatment
  3. AC Immune and Lilly Announce License and Collaboration Agreement
  4. Lilly and AC Immune Announce License and Collaboration Agreement
  5. In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away
  6. What You Must Know About AC Immune SA’s (NASDAQ:ACIU) Beta Value
  7. AC Immune (ACIU) Shares March Higher, Can It Continue?
  8. AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease
  9. AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates
  10. AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update
  11. AC Immune to Present at the Jefferies 2018 London Healthcare Conference
  12. AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases
  13. Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
  14. AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases
  15. AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620
  16. AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy
  17. AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona